Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 7Breast Neoplasms 7Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Recurrence 3Pancreatic Neoplasms 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Congenital Abnormalities 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × tipifarnib × Clear all
NCT02464228 2024-06-26

PTCL

Kura Oncology, Inc.

Phase 2 Completed
65 enrolled 16 charts
Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00847223 2018-08-23

Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma

Lymphoma Study Association

Phase 2 Terminated
11 enrolled
Lymphoid

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT00354146 2011-02-01

A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
252 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡